A citation-based method for searching scientific literature

Harpreet S Bajaj, Itamar Raz, Ofri Mosenzon, Sabina A Murphy, Aliza Rozenberg, Ilan Yanuv, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Marc S Sabatine, Stephen D Wiviott, Avivit Cahn. Diabetes Obes Metab 2020
Times Cited: 5







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
80

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
Remo H M Furtado, Marc P Bonaca, Itamar Raz, Thomas A Zelniker, Ofri Mosenzon, Avivit Cahn, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
83
60

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
60

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
764
60


Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar,[...]. Diabetes Obes Metab 2018
89
40

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
143
40

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
171
40

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Naveed Sattar, Björn Eliasson, Ann-Marie Svensson, Björn Zethelius, Mervete Miftaraj, Darren K McGuire, Annika Rosengren,[...]. N Engl J Med 2018
293
40

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
40

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
383
40

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
40

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
326
40

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
163
40

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson,[...]. Lancet Diabetes Endocrinol 2017
161
40

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
165
40

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
707
40

Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes.
Allie S Carew, Andrew P Levy, Henry N Ginsberg, Steven Coca, Orit Lache, Thomas Ransom, Robert Byington, Eric B Rimm, John Sapp, Martin Gardner,[...]. J Am Coll Cardiol 2020
8
20

Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.
George Hripcsak, Marc A Suchard, Steven Shea, RuiJun Chen, Seng Chan You, Nicole Pratt, David Madigan, Harlan M Krumholz, Patrick B Ryan, Martijn J Schuemie. JAMA Intern Med 2020
12
20


Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
Yao Qiao, Jung-Im Shin, Teresa K Chen, Lesley A Inker, Josef Coresh, G Caleb Alexander, John W Jackson, Alex R Chang, Morgan E Grams. JAMA Intern Med 2020
14
20

Acupuncture for painful diabetic neuropathy.
Zachary Bloomgarden. J Diabetes 2019
1
100

Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY).
William B White, Dorothy B Wakefield, Nicola Moscufo, Charles R G Guttmann, Richard F Kaplan, Richard W Bohannon, Douglas Fellows, Charles B Hall, Leslie Wolfson. Circulation 2019
22
20

Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms: A Randomized Clinical Trial.
Ting Bao, Sujata Patil, Connie Chen, Iris W Zhi, Qing S Li, Lauren Piulson, Jun J Mao. JAMA Netw Open 2020
7
20

Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Marie C Bradley, Yoganand Chillarige, Hana Lee, Xiyuan Wu, Shruti Parulekar, Michael Wernecke, Patricia Bright, Mat Soukup, Thomas E MaCurdy, Jeffrey A Kelman,[...]. Diabetes Care 2020
2
50


Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
Chiara Saponaro, Markus Mühlemann, Ana Acosta-Montalvo, Anthony Piron, Valery Gmyr, Nathalie Delalleau, Ericka Moerman, Julien Thévenet, Gianni Pasquetti, Anais Coddeville,[...]. Diabetes 2020
16
20


ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.
Marie Pigeyre, Jennifer Sjaarda, Michael Chong, Sibylle Hess, Jackie Bosch, Salim Yusuf, Hertzel Gerstein, Guillaume Paré. Diabetes Care 2020
5
20

Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
Yamini Natarajan, Jennifer R Kramer, Xian Yu, Liang Li, Aaron P Thrift, Hashem B El-Serag, Fasiha Kanwal. Hepatology 2020
7
20

Associations of serum magnesium levels and calcium-magnesium ratios with mortality in patients with coronary artery disease.
Q Li, Q Chen, H Zhang, Z Xu, X Wang, J Pang, J Ma, W Ling, D Li. Diabetes Metab 2020
1
100

Follicle-stimulating hormone and estradiol are associated with bone mineral density and risk of fractures in men with type 2 diabetes mellitus.
Yixuan Jing, Xiaofeng Wang, Jingjia Yu, Xiaojing Wang, Yanman Zhou, Bei Tao, Lihao Sun, Jianmin Liu, Hongyan Zhao. J Diabetes 2020
1
100

Talks and tweets from the ADA.
Zachary Bloomgarden. J Diabetes 2018
1
100


The importance of hyperosmolarity in diabetic ketoacidosis.
S P Blank, R M Blank, M D Ziegenfuss. Diabet Med 2020
1
100

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program.
Louis Potier, Ronan Roussel, Marianne Zeller, François Schiele, Etienne Puymirat, Tabassome Simon, Nicolas Danchin. Diabetes Care 2020
2
50

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.
Mario Luca Morieri, Hetal S Shah, Jennifer Sjaarda, Petra A Lenzini, Hannah Campbell, Alison A Motsinger-Reif, He Gao, Laura Lovato, Sabrina Prudente, Assunta Pandolfi,[...]. Diabetes 2020
3
33

Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
Marwan Saad, Ahmed N Mahmoud, Islam Y Elgendy, Ahmed Abuzaid, Amr F Barakat, Akram Y Elgendy, Mohammad Al-Ani, Amgad Mentias, Ramez Nairooz, Anthony A Bavry,[...]. Int J Cardiol 2017
40
20

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
L Rossetti, D Smith, G I Shulman, D Papachristou, R A DeFronzo. J Clin Invest 1987
517
20

Cardiovascular safety of anti-diabetic drugs.
R Kumar, D M Kerins, T Walther. Eur Heart J Cardiovasc Pharmacother 2016
26
20

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero, Angelo Avogaro. Cardiovasc Diabetol 2017
37
20

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study.
Daniala L Weir, Finlay A McAlister, Ambikaipakan Senthilselvan, Jasjeet K Minhas-Sandhu, Dean T Eurich. JACC Heart Fail 2014
91
20

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
76
20

DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
126
20


Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
370
20

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
186
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.